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Triggering receptor expressed on myeloid
cells-2 expression in the brain is required
for maximal phagocytic activity and
improved neurological outcomes
following experimental stroke
Kota Kurisu1,*, Zhen Zheng1,*, Jong Youl Kim1, Jian Shi1,
Atsushi Kanoke2, Jialing Liu2, Christine L Hsieh3 and
Midori A Yenari1
Abstract
Triggering receptor expressed on myeloid cells-2 (TREM2) is an innate immune receptor that promotes phagocytosis by
myeloid cells such as microglia and macrophages. We previously showed that TREM2 deficiency worsened outcomes
from experimental stroke and impeded phagocytosis. However, myeloid cells participating in stroke pathology include
both brain resident microglia and circulating macrophages. We now clarify whether TREM2 on brain microglia or
circulating macrophages contribute to its beneficial role in ischemic stroke by generating bone marrow (BM) chimeric
mice. BM chimera mice from TREM2 knockout (KO) or wild type (Wt) mice were used as donor and recipient mice.
Mice were subjected to experimental stroke, and neurological function and infarct volume were assessed. Mice with
intact TREM2 in brain microglia showed better neurological recovery and reduced infarct volumes, compared with mice
lacking microglial TREM2. Myeloid cell activation and numbers of phagocytes were decreased in mice lacking brain
TREM2, compared with mice with intact brain TREM2. These results suggest that TREM2 expression is important for
post-stroke recovery, and that TREM2 expression on brain resident microglia is more essential to this recovery, than that
of circulating macrophages. These findings might suggest a new therapeutic target for cerebrovascular diseases.
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Introduction
Innate immune responses accompanying ischemic
stroke involve various immune cells and various path-
ways which interact with one other, and contribute sig-
niﬁcantly to stroke pathophysiology.1,2 Microglia are
the brain’s resident immune cell and recent work has
shown that these cells play a crucial role in the brain’s
immune response, not only in brain ischemia, but in
other brain diseases. Microglia are the brain’s resident
myeloid-lineage cells involved in constant immune sur-
veillance.3 Like other myeloid cells, they are capable of
transforming into phagocytes, and have thus been
referred to as ‘brain macrophages’.1,2 To date, numer-
ous studies4,5 have been performed to clarify the role of
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microglia in stroke pathophysiology, including its func-
tions in chemotaxis, secretion of pro-inﬂammatory
and anti-inﬂammatory cytokines, growth factors,
chemokines, proteases, and neurotrophins. Currently,
regulation and modulation of this multifunctional
cell have been investigated as a novel therapeutic
target in stroke.
Among these many microglial functions, its phago-
cytic properties have been intensely studied in several
brain disease models. Several phagocytic pathways
have been identiﬁed in the past,6 and the eﬃcient clear-
ance of tissue debris is thought to be critical in the
reconstruction and reorganization of neuronal net-
works. Recent work in the area of stroke has demon-
strated that microglia possess both damaging and
beneﬁcial properties depending on the timing and spe-
ciﬁc phenotype.7 We previously reported a beneﬁcial
role of microglial phagocytosis, which was promoted
by the innate immune molecule, triggering receptor
expressed on myeloid cells-2 (TREM2) in experimental
stroke models.8,9 We showed that in a paradigm of
neuroprotection by therapeutic hypothermia, TREM2
was upregulated to a greater extent in myeloid cells
within the ischemic brain. By studying mice deﬁcient
in TREM2, we found that these mice had worsened
neurological outcomes compared to wildtype.8 In line
with our previous reports, recent studies from other
groups similarly reported a beneﬁcial role of TREM2
in ischemic brain.10,11
TREM2 was originally described on circulating
macrophages, where it bound anionic moieties on bac-
teria and yeast and led to their phagocytosis.12 TREM2
is uniquely expressed on myeloid cells,13,14 as it is not
observed on granulocytes and lymphoid cells such as
neutrophils and lymphocytes.12 In the brain, it is only
expressed on microglia,15,16 although not all microglia
express TREM2.17 Both macrophages recruited from
circulation and microglia derived from the brain
itself, have the ability to phagocyte ischemia-damaged
tissues.18 Therefore, TREM2 may be acting through
microglia and/or circulating macrophages to carry out
its phagocytic functions in stroke. However, it is
unknown which pool of TREM2 positive cells is
responsible for its phagocytic functions.
To explore which pool of myeloid cells contributes
to TREM2’s eﬀect in ischemic stroke, we conducted the
present study by employing a bone marrow (BM) chi-
meric mouse model. BM chimeric mice are created
when BM from a donor strain is transplanted
into recipient mice, whose marrow had been ablated.
This model allows for the study of marrow related con-
tributions to a particular pathology.18–21 This experi-
mental approach has enabled us to distinguish




All experimental procedures were approved by the
San Francisco Veterans Aﬀairs Medical Center
Institutional Animal Care and Use Committee, and
were in accordance with National Institutes of Health
and ARRIVE (Animal Research: Reporting In Vivo
Experiments) guidelines.
Male TREM2 knock-out (KO) mice and wild-type
(Wt) littermates, which were originally generated by
Colonna and colleagues (Washington University,
St.Louis, MO),22 were used as previously described.8
These mice were backcrossed for over ﬁve generations.
Green ﬂuorescent protein (GFP) transgenic mice were
also used as donors, in pilot experiments to develop and
validate the BM chimera model.
Generation of BM chimeric mice
BM from donor mice (male, two to three months of
age, KO or Wt mice) was harvested from the femurs.
Cells were suspended in 2% bovine calf serum (BCS).
Prior to BM transplantation, recipient mice (male, two
to three months of age, KO or Wt mice) were treated
with busulfan (25mg/kg/d) for ﬁve days to ablate
endogenous BM. Recipient mice were given 2 107
donor BM cells in 200 ml PBS via a tail vein.20 The
resulting chimeric mice were housed in autoclaved
cages with sterile water containing antibiotics to allow
complete reconstitution of BM before use in further
experiments.
In pilot studies to validate this approach in our lab,
GFP transgenic mice (C57BL/6-Tg (CAG-
EGFP)1Osb/J, Jackson Labs) were used as donors,
while Wt mice were used a recipients. After receiving
donor marrow, mice were survived 80 days, after which
brains were harvested for histology and ﬂow cytometry.
Some of these mice also underwent stroke surgeries
(see below).
Chimeric mice derived from the TREM2 KO strain
were divided into four groups: Wt to Wt group (Wt BM
transplanted into Wt mice), KO to Wt (KO BM trans-
planted into Wt mice), Wt to KO (Wt BM transplanted
into KO mice), KO to KO (KO BM transplanted into
KO mice) (Figure 1(a)). These mice also underwent
stroke surgeries 80 days post transplantation.
Flow cytometry
After collection of whole blood samples in EDTA at
the time of euthanasia, cells were suspended in cell lysis
buﬀer to remove red blood cells.23 Cell suspensions
were transferred to a 40 mm pore size ﬁlter, ﬁxed in
BD Cytoﬁx (BD Biosciences, Cat No: 554714) and
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resuspended in 400 ul of ice cold FBS (BD Pharmingen,
Cat No:554656). Samples were analyzed on a
FACSCalibur ﬂow cytometer (Becton Dickinson
Immunocytometry Systems, BDIS) at the San
Francisco VAMC Flow Cytometry Core facility using
FL-1, FSC and side scatter detectors. Green eGFP
ﬂuorescence was measured in the FL1 channel. On
each sample, 10,000 events were acquired within the
single gate. The analysis of data was performed with
CELLQuest software (BDIS).
Stroke model
All surgical techniques were performed under aseptic
conditions. After approximately two months following
BM transplantation, stroke surgery was performed
under gas anesthesia. Anesthesia was induced by the
inhalation of 3.0% isoﬂurane in medical air: O2
(80%:20%). Surgical planes of anesthesia were assessed
by the absence of hindleg withdrawal in response to a
pinch. A 1 cm skin incision was created between the left
margin of the orbit and the tragus, and the temporalis
muscle was incised. A focal cerebral infarct was induced
by permanent occlusion of the distal left middle cere-
bral artery (dMCAO) as previously described.8,24
Brieﬂy, a small craniotomy was made above the prox-
imal segment of middle cerebral artery (MCA) and the
MCA was exposed after the dura was opened and
retracted. The MCA was occluded by coagulation at
the MCA segment just proximal to the olfactory
branch. Rectal temperature was maintained between
36.5C and 37.5C during the procedures by using a
Figure 1. Scheme of the experimental design and validation of the bone marrow (BM) chimera model in mice. (a) Wildtype (Wt) and
TREM2 knockout (KO) mice were used as BM donors (Bone marrow) or hosts (Brain). Four permutations representing four
experimental groups are studied. (b) Following endogenous BM ablation with busulfan, BM from green fluorescent protein transgenic
(GFP Tg) mice was transplanted into Wt mice (n¼ 3). Blood samples were collected and subjected to flow cytometry. No GFP
positive cells (y-axis) were present in circulating leukocytes from non-transplanted control mice (control, top graph). By 40 days post
BM transplantation, 74% of cells in from the circulation were GFP positive (middle graph). By 80 days post transplantation (bottom
graph), 95% of circulating cells were GFP positive, and suggests near complete turnover of the endogenous BM by the GFP
transgenic BM. (c) Mice were transplanted with GFP Tg BM, then subjected to dMCAO 80 days later. Immunofluorescence of brains
from a GFP BM chimeric mouse is shown one day post dMCAO. In the ipsilateral peri-infarct region, several GFP positive cells are
observed (arrows) and are presumed to derive from the circulation. In the contralateral non ischemic hemisphere, no GFP positive
cells could be seen, nor were any GFP positive cells observed in sham control chimeras (not shown). Thus, transplanted BM did not
turnover any endogenous brain cells at the time of the stroke surgeries.
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thermometer connected to a heating pad. At the end of
surgery, incision sites were closed and animals were
allowed to recover. Mice were returned to their cages
and allowed free access to food and water, and were
housed in a climate-controlled environment (25C).
Mice were included in the study if they showed neuro-
logical deﬁcits as deﬁned by a Bederson score of at least
3 (circling behavior) at 24 h post dMCAO.25
Behavior assays
Neurological assessments were performed before sur-
gery and 2, 7, and 14 days after stroke as previously
described.26 All studies were recorded using a video
camera, and scoring was performed by two diﬀerent
investigators blinded to experimental conditions.
Elevated body swing test. To measure motor deﬁcits, mice
were suspended vertically by the tail with their heads
elevated three inches above the test bench. A lateral
swing was counted each time the animal moved its
head >10 away from the vertical axis. Counts were
carried out for four 15-s sessions, and the frequency
of right-biased swing was calculated.26,27
Adhesive removal test. Circular adhesives (4mm diam-
eter) were attached to the palm of each forepaw, and
mice were observed for 2min and scored for identifying
the time it took for the mouse to detect the adhesive
(contact time), and the time it took to remove it
(removal time).
Histology
Fourteen days post stroke, animals were euthanized
with an anesthesia overdose, perfused transcardially
with ice-cold normal saline. Brains were harvested,
sunk in 30% sucrose overnight and frozen at 80C.
Frozen sections (20mm thickness) were cryosectioned in
the coronal plane.
Measurement of infarct volume. Brain sections were
stained with cresyl violet to measure infarct size as pre-
viously described.8,28 Coronal sections from six brain
regions between 1.5mm anterior and 1.5mm posterior
to the bregma) were collected at 500mm intervals
throughout the ischemic lesion and stained with cresyl
violet. We identiﬁed areas of damage depending on
microscopic evidence of cell death (loss of normal
brain architecture, presence of gliosis, loss of tissue,
damaged cell morphology). The infarct areas in each
section were measured using an image analysis system
(ImageJ) and calculated by subtracting the normal ipsi-
lateral area from that of the contralateral hemisphere to
correct for brain edema.
Immunohistochemistry and immunofluorescence. Tissue
sections were stained by peroxidase-labeled Griﬀonia
simplicifolia isolectin-B4 (IB4) (10 g/ml; L5391,
Sigma) followed by diaminobenzidine (Vector
Laboratories) to identify microglia and other myeloid
lineage cells. To visualize the lipid-rich foamy macro-
phages (phagocytes), Oil red O staining (O0625, Sigma)
was used according to the instructions of the manufac-
turer followed by hematoxylin counterstaining. In
order to assess TREM2 expression on these immune
cells, sections were colabeled for CD11b, to identify
microglial/macrophages/monocytes, and TREM2.
Sections were reacted with primary antibodies against
CD11b (rabbit polyclonal, 1:200; ab75476, Abcam) and
TREM2 (rat monoclonal, 1:50; MAB17291, R&D
Systems) at 4C overnight. Sections were then reacted
with Alexa Fluor 488-conjugated goat anti-rabbit IgG
(1:400, Life Technologies) and Alexa Fluor-594 conju-
gated goat anti-rat IgG (1:200, Life Technologies) at
room temperature for 1 h. To assess for TREM2
expression on phagocytes, sections were colabeled
with the macrophage marker CD68 plus TREM2.
Sections were incubated with primary antibodies
against CD68 (rabbit polyclonal, 1:1000; MBS175328,
My Bio Source) and TREM2 (rat monoclonal, 1:200;
MAB17291, R&D Systems) at 4C overnight. Sections
were then reacted with Alexa Fluor 488-conjugated
goat anti-rabbit IgG (1:400, Life Technologies) and
Alexa Fluor 594-conjugated goat anti-rat IgG (1:200,
Life Technologies) at room temperature for 1 h.
Positive cells were counted under optical microscopy
(BX-53 microscope, Olympus) or laser confocal micros-
copy (LSM510, Zeiss), as previously described.8,21
Brieﬂy, a section 1mm anterior to the bregma was
used to quantify the cell numbers, and positive cells
were counted from ﬁve random nonoverlapping high-
power ﬁelds (HPFs) (400 for optical microscopy, and
630 for laser confocal microscopy) within the cortex
adjacent to the outer boundary of the infarct, as deli-
neated by the hematoxylin stain.
Statistical analysis, RIGOR criteria
All experimental groups were studied in a randomized
fashion, and rating and lesion analyses were performed
by investigators blinded to experimental conditions.
Sample size calculations were performed based on our
prior studies with this stroke8 and BM chimeric21
models. All statistical analyses were performed using
Sigma Stat version 3.1 (Systat software). All data were
presented as the mean SD. The diﬀerences between the
two groups were compared using an unpaired t-test, and
multiple comparisons were performed using one-way
ANOVA followed by Bonferroni’s post hoc test where
data were normally distributed. For behavior test
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analysis, two-way ANOVA was applied. Non-para-
metric tests of Mann–Whitney or Wilcoxon Rank Sum
were applied where data were not normally distributed.
P< 0.05 was considered signiﬁcant.
Results
All animals survived the stroke and sham surgeries.
There were no mortalities and no exclusions.
Validation of the BM chimera mouse model
Our prior work using BM chimeras involved the abla-
tion of endogenous marrow by irradiation.21 In this
approach, animals required sedation and head shielding
prior to irradiation which led to near complete turnover
of endogenous marrow without detection of trans-
planted marrow cells into the brain or evidence of
brain injury that could have been caused by the irradi-
ation. In our current approach, we elected to ablate BM
pharmacologically with busulfan, which was shown in
prior reports to have fewer complications such as
stimulation of the endogenous immune system, and
ease of implementation.20 To validate this approach
in our hands, BM from GFP transgenic donor mice
was transplanted into Wt host mice (n¼ 3). Blood sam-
ples were collected and subjected to ﬂow cytometry
before, 40 days and 80 days after BM transplantation
(Figure 1(b)). As expected, ﬂow cytometry showed no
GFP positive cells (presented by y-axis) in circulating
leukocytes from non-transplanted control mice. Among
chimeric mice, 74% of leukocytes were GFP positive by
40 days and 95% by 80 days.
These GFP chimeric mice were also subjected to
stroke (dMCAO), and brain were collected one day
later. Figure 1(c) shows several GFP positive cells
within the peri-infarct areas of the brain (arrows),
and is consistent with inﬁltrating leukocytes into areas
of infarction. On the contralateral non-ischemic side
(contralateral), no GFP positive cells were observed.
Further, in GFP chimeric mice that underwent sham
surgery, no GFP positive cells could be seen in the
intact brain (not shown). These data indicate that our
model not only led to near complete turnover of the
host’s endogenous BM, but that there was no turnover
of any brain cells from the transplanted marrow after
80 days. Thus, this model could be used to diﬀerentiate
contributions from brain-derived versus marrow-
derived immune cells.
Mice with intact TREM2 in brain microglia had more
favorable neurological recovery
Sensorimotor tests were carried out prior to stroke and
2, 7 and 14 days later. Mice with intact TREM2 in the
brain (Wt to Wt and KO to Wt groups; n¼ 6/group)
performed better on the elevated body swing test
(Figure 2(a)) on days 7 and 14, compared with those
that lacked TREM2 in the brain (Wt to KO and KO to
KO groups). Similarly, these same groups performed
better on two diﬀerent measures from the adhesive
removal test (Figure 2(b)). There were no signiﬁcant
diﬀerences in neurological recovery when Wt mice
were transplanted with TREM2 KO BM (KO to Wt
vs. Wt to Wt). TREM2 KO mice did not have better
neurological recovery when transplanted with Wt BM
(Wt to KO vs. KO to KO). These results indicate that
amongst mice with resident brain cells containing intact
TREM2 fared better, regardless of the status
of TREM2 in their BM, compared to those that
lacked TREM2 in the brain. Since we and others
have previously shown that TREM2 is expressed exclu-
sively in myeloid cells,8,13,14,16,17 it is reasonable to con-
clude that the eﬀects of TREM2 occur within the brain
through microglia.
Mice with intact TREM2 in brain microglia had
smaller infarcts
Infarct size 14 days after dMCAO from all four BM
chimera groups were compared (Figure 3). In line with
neurological assessments, groups with intact TREM2 in
brain microglia (KO to Wt (12.9 5.8%; n¼ 6) and Wt
to Wt (11.6 1.2%) groups; n¼ 6) had signiﬁcantly
smaller infarct volumes compared to groups lacking
brain TREM2 (KO to KO (24.1 9.3%; n¼ 6) and
Wt to KO (18.1 5.2%; n¼ 6) groups). Further,
replacement of intact TREM2 (Wt to KO) in
TREM2 deﬁcient mice (KO to KO) showed a trend
towards reduced infarct volume. Also of note, amongst
brains of both groups of KO mice, we failed to observe
tissue resorption by 14 days, while brain tissue loss was
seen in Wt mice (Figure 3(a)). Areas of reactive gliosis
were observed within all ischemic brain regions, but
this was not signiﬁcantly aﬀected by the absence of
TREM2.
Fewer activated microglia/macrophages in TREM2
KO mice, graded response with BM transplantation
Activated microglia and macrophages were identiﬁed
by IB4 staining, and were counted at the infarct
border 14 days after stroke (Figure 4). The number of
activated microglia and macrophages was signiﬁcantly
decreased in descending order: Wt to Wt, KO to Wt,
Wt to KO, KO to KO (n¼ 6/group). In addition, we
investigated whether there may be a strong correlation
between infarct volume and the number of IB4 positive
cells by regression analysis. As shown in Supplemental
Figure 1, our model showed a negative correlation
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between number of activated myeloid cells and infarct
volume (r¼0.63, P< 0.001).
Colabeling with CD11b and TREM2 was performed
to identify the expression of TREM2 on microglia/
macrophages (Figure 5). TREM2 (red) colocalized
exclusively to CD11b positive (green) cells
(Figure 5(a)). Total numbers of colabeled cells
(Figure 5(b)) followed the same pattern as that seen
Figure 2. Neurological assessments showed worsened deficits in mice that lacked TREM2 in the brain. (a) Elevated body swing test
showed significantly worse performance in Wt to KO and KO to KO groups, compared to Wt to Wt and KO to Wt groups 7 and 14
days post stroke as evidenced by greater right sided bias. (b) Adhesive removal test showed worsened sensorimotor function 7 and
14 days in Wt to KO and KO to KO groups compared to Wt to Wt and KO to Wt groups as evidenced by both longer contact and
adhesive removal times. (*P< 0.05, **P< 0.01; n¼ 6/group).
Figure 3. Ischemic lesion size in BM chimera mice. (a) Representative cresyl violet-stained sections 14 days post-dMCAO of each
experimental group are shown. Of note, brains from the KO to KO and Wt to KO mice showed areas of pallor within the ischemic
territory and lack of tissue resorption. In contrast, brains from the Wt to Wt and KO to Wt brains showed more brain tissue loss
compared to KO. Reactive gliosis (darker staining within the ischemic lesions) was observed in all brains, but not significantly affected
by TREM2 deficiency. (b) Quantification of infarct sizes are shown. Groups with intact brain TREM2 (KO to Wt (12.9 5.8%) and Wt
to Wt (11.6 1.2%) groups) had significantly smaller lesions compared to groups that lacking brain TREM2 (KO to KO (24.1 9.3%)
and Wt to KO (18.1 5.2%) groups). (*P< 0.05, **P< 0.01; n¼ 6/group).
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with IB4 staining. The numbers of TREM2/CD11b
colabeled cells were signiﬁcantly decreased in descend-
ing order: Wt to Wt, KO to Wt, Wt to KO, KO to KO
(n¼ 6/ group). These results suggest that intact TREM2
on brain microglia, rather than on circulating micro-
phages, contributed more to the accumulation of these
cells to the infarct borderzone. It should also be pointed
out that the few TREM2 positive cells observed among
KO to KO brains appeared as faint round spots
(Figure 5(a), KO to KO row), of which a few appeared
to overlay some CD11b positive cells (Merge). While
these likely represent artifact from the secondary anti-
body, they could have alternatively represented very
low levels of TREM2. The latter seems unlikely, as
our prior work validating the TREM2 KO model indi-
cated total lack of TREM2 protein expression.8
Figure 5. TREM2 expression amongst microglia/macrophages in BM chimera mice. (a) Brain sections were colabeled with TREM2
(red) and the microglia/macrophage marker CD11b (green). DAPI stain was used to identify nuclei (blue). Immunofluorescence stains
show that TREM2 colocalized exclusively to CD11b positive cells, but not all CD11b positive cells were TREM2 positive. (b) Counts of
coloabeled cells were significantly decreased in order: Wt to Wt (81.0 31.0 cells/HPF), KO to Wt (66.3 32.2 cells/HPF), Wt to KO
(30.3 9.1 cells/HPF), KO to KO (16.8 10.5 cells/HPF). (*P< 0.05, **P< 0.01; n¼ 6/group).
Figure 4. Reduced microglia/macrophages in mice lacking brain TREM2. Microglia/macrophages were identified by isolectin-B4 (IB4)
staining. Deeper staining with thickened or absent processes and enlarged cell bodies were used to identify activated microglia/
microglia. (a) Representative images of IB4 staining of each group are shown. (b) Counts of IB4 positive activated microglia/macro-
phages were highest amongst Wt to Wt mice (133.3 67.0 cells/HPF) and the lowest in the KO to KO group (17.0 12.4 cells/HPF).
The other two experimental groups had intermediate counts, but there were more positive cells in the KO to Wt group (104.0 45.1
cells/HPF) compared to Wt to KO (36.4 17.8 cells/HPF). (*P< 0.05, **P< 0.01; n¼ 6/group).
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More phagocytosis observed in mice with intact
TREM2 in the brain
Oil red O staining was used to detect intracellular lipids
as a functional indicator of myeloid cells capable of
phagocytosis (Figure 6). Experimental groups with
intact TREM2 expression in the brain (KO to Wt
and Wt to Wt groups; n¼ 6/group) demonstrated
more oil red positive cells (foamy macrophages phago-
cytes), compared to mice lacking TREM2 in the brain
(Wt to KO and KO to KO groups) (Figure 6(a) and (b))
Because TREM2 deﬁciency in microglia and/or macro-
phage is aﬀecting on the total number of myeloid cell
accumulation in ischemic brain (Figure 4), the number
of oil-red O positive cells in each mice was divided by
the number of IB4 positive cells. This average percent-
age estimates phagocytic capacity (Figure 6(c)).
This result further conﬁrmed that phagocytic capacity
is signiﬁcantly higher in mice with intact TREM2 in the
brain, compared to mice lacking TREM2 in brain.
Colabeling with CD68 and TREM2 was performed
to identify the expression of TREM2 on phagocytes
(Figure 7). In the present study, CD68 was used as
marker of phagocytic cells. First, we investigated the
percentage of phagocytic CD11b positive cells
(CD68þCD11bþ) in each mouse (Supplemental
Figure. 2). In line with oil red O staining, the result
demonstrated that the percentage of phagocytes was
signiﬁcantly decreased in descending order: Wt to Wt,
KO to Wt, Wt to KO, KO to KO.
We then analyzed colocalization of TREM2 (red)
and CD68 (green). TREM2 positive cells colocalized
exclusively to CD68 positive cells (Figure 7(a)). Both
the total numbers of double-labeled cells (Figure 7(b))
and the proportion of double labeled (TREM2þ
CD68þ) cells to all CD68þ cells (Figure 7(c)) were
signiﬁcantly decreased in the order of Wt to Wt,
KO to Wt, Wt to KO, and KO to KO groups
(n¼ 6/group). These results indicate that intact
TREM2 in the brain contributes more to phagocyt-
osis compared to TREM2 on circulating microphage.
That there are signiﬁcant diﬀerences between the
KO to Wt and Wt to KO with more oil red and
double positive cells amongst the KO to Wt group,
suggests that brain resident cells with intact TREM2
contribute more to phagocytosis than those from the
circulation.
Figure 6. TREM2 deficiency in the brain leads to near complete absence of phagocytosis. Oil red staining was used to identify
functional phagocytosis in brain sections. (a) Representative images of oil red staining of each group are shown. Near complete
absence of oil red positive cells was seen in brains of TREM2 KO mice, compared to Wt, regardless of their marrow status. (b) Counts
of oil red foamy macrophages were lowest where the host animal was TREM2 deficient (Wt to KO: 3.2 6.2 cells/HPF); KO to
KO:1.0 1.0 cells/HPF) compared to Wt host animals (KO to Wt: 50.5 20.9 cells/HPF; Wt to Wt:93.4 49.4 cells/HPF). (c) To
reflect the phagocytic capacity in each mouse, the number of oil red foamy macrophages was divided by the average number of IB4-
stained cells. The average percentage was higher in Wt host animals (KO to Wt: 48.7 15.9%; Wt to Wt: 66.2 15.8%), compared to
TREM2 deficient (Wt to KO: 6.9 13.0%); KO to KO:5.7 5.5%) (*P< 0.05, **P< 0.01; n¼ 6/group).
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Discussion
Immune responses accompanying stroke involve both
circulating leukocytes and microglia, the brain’s
endogenous immune cell. Recent work has demon-
strated the complexity of this response, which has
proven to be both damaging and beneﬁcial depending
on the cell type and the time period after the
insult.1,29,30 A beneﬁcial property of this immune
response is that phagocytosis and removal of necrotic
tissue are essential prior to repair.31,32 One immune
receptor involved in this phagocytosis appears to be
TREM2. TREM2 is a single-spanning membrane
receptor belonging to the immunogloblin-lectin-like
superfamily and is expressed exclusively on myeloid
cells, including macrophages and microglia.13,14,22,33 It
was ﬁrst described on the surface of circulating macro-
phages and brain resident microglia, where it bound
various pathogens and participated in immune surveil-
lance function.12 Once activated, TREM2 engages its
adapter protein, DAP12 (DNAX-activating protein of
12 kDa) ultimately triggering phagocytosis.22
To date, work concerning TREM2 in the brain
has focused largely on neurodegenerative diseases,
especially Alzheimer’s.34 In humans, TREM2 gene vari-
ants have been linked to an increased risk of the devel-
opment of Alzheimer’s disease,35 and genetic disruptions
of TREM2 or its adapter protein DAP12 have been
associated with a rare degenerative brain disease
(Nasu-Hakola disease).36 In models of Alzheimer’s,
TREM2 has been shown to promote microglial phago-
cytosis of amyloid and amyloid-induced proinﬂamma-
tory reactions.37,38 Overexpression of TREM2
prevented neuron loss, preserved synapses and improved
cognitive function, while decreasing expression of proin-
ﬂammatory cytokines.37,38 Although the precise mechan-
isms underlying TREM2’s loss of function due to these
mutations are unclear, these ﬁndings support the notion
that TREM2 is necessary for the maintenance of normal
brain function.
The role of TREM2 in acute brain insults has
been less studied, but we and others showed that
TREM2 deﬁciency worsened outcome in experimental
stroke.8,9,11 In a previous paper from our group, we
showed TREM2 upregulation in a tMCAO model of
mice treated with therapeutic hypothermia.9,39
Furthermore, we demonstrated worsened neurological
recovery and larger infarct volumes in TREM2
Figure 7. Proportions of TREM2 positive macrophages in BM chimeric mice. Brain sections were stained with TREM2 (red) and the
macrophage marker CD68 (green). (a) Representative immunofluorescence images show that all TREM2 positive cells colocalize
exclusively to a subset of CD68 positive cells (Merge, yellow). Fewer CD68 positive and fewer colabeled cells were observed where
the host animal was TREM2 deficient. Counts of double-labeled cells showed that both the total number of double labeled (b) and
proportion of TREM2 positive cells among CD68 positive cells (c) were significantly decreased, in order of Wt to Wt (num-
ber:64.3 20.0 cells/HPF; proportion 87.7 10.9%), KO to Wt (number:36.7 18.4 cells/HPF; proportion 56.8 18.8%), Wt to KO
(number:12.5 6.3 cells/HPF; proportion 47.7 21.6%), KO to KO group (number:0.7 0.9 cells/HPF; proportion 4.4 5.8%).
(*P< 0.05, **P< 0.01; n¼ 6/group).
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deﬁcient mice.8 In this experimental model, TREM2
expression peaked around seven days post stroke. We
also observed that phagocytes deﬁcient in TREM2
could not engulf apoptotic/necrotic cells, which led to
the impairment of resorption of ischemic tissue.8 We
considered that this inability to clear damaged tissue
may have led to increased damage to neighboring
tissue through continued elaboration of DAMPs
(damage-associated molecular patterns) and/or a
crowding eﬀect. Although it seems that TREM2 plays
a crucial role in post-stroke recovery, there are clearly
questions that remain.
Here, we reproduced our prior ﬁndings that
TREM2 deﬁciency worsened outcomes from experi-
mental stroke and impeded phagocytosis. We further
demonstrate here through the use of a BM chimera
model that this eﬀect is mediated mostly through
brain resident microglia, rather than BM-derived cir-
culating macrophages, although nonsigniﬁcant diﬀer-
ences between the KO to Wt and Wt to Wt suggest
that there is a minor contribution from the circulat-
ing macrophages. TREM2 is unique to myeloid cells
and has been documented in macrophages, mono-
cytes, microglia and dendritic cells.13,40 It is not
expressed in other brain cell types such as neurons,
oligodendrocytes or astrocytes.11,14,16 TREM2 KO
mice transplanted with either Wt or KO BM had
worse outcomes than Wt mice, even amongst Wt
mice transplanted with KO BM. Thus, it is reason-
able to conclude that this eﬀect is a result of TREM2
deﬁciency in brain resident myeloid cells, of which
the majority is microglia.
However, whether TREM2 is beneﬁcial or detrimen-
tal to neurological conditions is still somewhat unclear.
The results presented here are in line with that previ-
ously reported by our group,8,9 as well as a few reports
from other groups. Wu et al.11 demonstrated that gen-
etic knock down of TREM2 exacerbated stroke out-
comes, while Zhai et al.10 showed that TREM2
overexpression was protective. Although it seems that
TREM2 confers beneﬁcial eﬀects in experimental ische-
mic stroke, there is a previous report that showed no
eﬀect of TREM2 deﬁciency in a related stroke model.41
There are also diﬀering reports of how TREM2 deﬁ-
ciency aﬀects outcome from other experimental neuro-
logical conditions. A few reports indicate that its
deﬁciency is actually associated with improved outcome
from experimental brain trauma42 and Alzheimer’s.14
Reasons for these discrepancies are unclear, but could
be explained by diﬀerences in the experimental models
and approaches. The study by Sieber and colleagues41
that failed to demonstrate a beneﬁcial eﬀect of TREM2
applied 30min transient MCA occlusion followed by
reperfusion, compared to the present study, which
applied permanent distal MCA occlusion. One
possibility is that their model, with a shorter duration
of ischemia, may not have suﬃciently activated the
endogenous immune response or, that because they uti-
lized a model of reperfusion, their model led to more
inﬁltration of BM-derived immune cells compared to
our model of permanent dMCAO which leads to
incomplete reperfusion through collateral vessels.8 It
is possible that immune cells in the brain in our
model may have been more microglia predominant,
whereas BM-derived macrophages that inﬁltrated the
brain may have predominated in their model. Our pre-
sent results may be consistent with this speculation, as
we observed a greater eﬀect of TREM2 expressed in the
brain resident microglia, rather than BM. However, an
earlier chimeric study by Schilling et al.18 similarly
showed that phagocytosis in a model of transient
MCAO was mediated more by brain resident microglia,
rather than in BM-derived macrophages, and supports
the notion that it is more likely to be microglia mediat-
ing phagocytosis, rather than whether MCAO is tran-
sient versus permanent.
Interestingly, others have shown that TREM2 deﬁ-
ciency leads to a potentiation of the immune
responses in related disease models.11,43 TREM2
overexpression has similarly been shown to inhibit
the production of pro-inﬂammatory cytokines, but
increasing the production of the anti-inﬂammatory
cytokine IL-10.11 Zhai et al.10 also reported its bene-
ﬁcial role through the regulation of microglial pheno-
types. They found that suppression of TREM2
enhanced microglial pro-inﬂammatory responses
while increasing neuronal apoptosis, whereas upregu-
lation of TREM2 ameliorated these deleterious eﬀects
and led to mostly anti-inﬂammatory responses. In
contrast, we found a relative deﬁciency of myeloid
cells among TREM2KO animals in our stroke
model both here and in our prior studies.8,9 This
cannot be explained by a baseline deﬁciency in micro-
glia, as counts of microglia in TREM2KO and Wt
nonischemic brains are similar (Supplemental Figure
1). To explain this, we speculated that TREM2 has
the eﬀect on microglia/macrophage’s mobilization
capacity. It is widely known that ischemic41stroke
induces accumulation of microglia/macrophages
toward the peri-ischemic lesion. We considered that
TREM2 may also regulate microglial migration cap-
acity, and not only phagocytic function. In support
of this, a recent study by Mazaheri et al.44 showed
that loss of TREM2 impaired microglial responses to
injury and suppressed signals that normally evoke
chemotaxis towards the injury site. Thus, we conclude
that, in stroke pathology, fewer accumulated micro-
glia/macrophages in TREM2 deﬁcient animals may
be explained by the reduced migration capacity
owing to the lack of TREM2 function. Such
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observations were seen not only in the present study
but also several previous papers.8,41 However, to
clarify the precise underlying mechanism, further
investigation is required. Nevertheless, TREM2 func-
tion in stroke pathophysiology seems to be crucial to
improving neurological outcome.
One important point of this study relates to whether
TREM2 induction or replacement may be a viable
therapeutic option for treatment of ischemic stroke.
We demonstrated better neurological recovery and
reduced infarct volume in mice with intact brain
TREM2 on microglia, compared to mice lacking
brain TREM2, regardless of TREM2 expression on
circulating macrophages. This observation implies
that novel therapy should be developed and designed
to target ‘brain resident microglia’ rather than circulat-
ing macrophages.
We should also point out that we do not know the
consequences of life long TREM2 deﬁciency in this
mouse model. In a related condition, Nasu Hakola dis-
ease, patients develop an early dementia along with
bony deformities. In our mouse model, TREM2 KO
mice did not have any gross abnormalities in brain
anatomy, even out to two years of age and failed to
show diﬀerences on cognitive assays (unpublished pre-
liminary observations). However, more detailed studies
in this mouse model may be needed, as well as the study
of conditional knockouts or activation/downregulation
of TREM2 in genetically intact adult mice. Second,
TREM2’s ligand is not well known, and could impede
the development of therapeutic strategies in patients.
This has been an issue that has plagued the ﬁeld in
general, but a few candidate molecules have been stu-
died. Although anionic moieties on bacteria and yeast12
are known ligands of TREM2 in the circulation, the
endogenous ligands in brain are still unclear. The 60
kDa heat shock protein (Hsp60) has been previously
shown to ligate TREM210,45; however, we were
unable to show that HSP60 could activate TREM2
an in vitro model (data not shown), and HSP60 was
not colocalized to TREM2 positive cells in our stroke
model.9 Our prior study did show that ischemic and
apoptotic neurons express and/or elaborate nucleic
acids/nucleic acid fragments which bind TREM2, and
leads to its activation in our stroke models,8 and
another group has shown that anionic and zwitterionic
lipids can also activate TREM2.46 Thus, it appears that
like other innate immune receptors, TREM2 can be
activated by typical danger-associated molecular pat-
terns (DAMPs). This should not be particularly surpris-
ing, considering its role in innate immunity, but further
investigation in this area is needed.
A limitation of the present study is that we were
not able to completely identify the role and function
of brain resident microglia and circulating
macrophages individually. We demonstrated better
recovery from stroke and more pronounced phagocy-
totic activity, when TREM2 is present in brain
microglia compared to that of circulating macro-
phages. This indirectly indicates that TREM2 expres-
sion on brain microglia is more important than that
of BM macrophage in stroke recovery. However, it is
still unclear what the functional diﬀerences of these
cells are, and how these diﬀerences aﬀect post-stroke
recovery. In order to clarify this question, the use of
chimera models where TREM2 deﬁcient cells could
be tagged would be helpful, and should be addressed
in future research.
In conclusion, we demonstrated that TREM2
expression on brain microglia and circulating macro-
phages led to better neurological recovery. The better
neurological recovery and beneﬁcial eﬀect were pre-
dominantly conferred when TREM2 was present in
brain microglia. We also show that not all microglia
express TREM2. These observations would suggest
an opportunity for clinical translation, whereby
TREM2 expression should be targeted speciﬁcally to
the brain. These novel ﬁndings might be useful in
developing new therapeutic strategies for related
neurological conditions as well.
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